Lyme disease

News

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.

News

Data builds behind Valneva, Pfizer's Lyme disease vaccine

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme

News

Protocol violations gut Pfizer’s Lyme disease shot study

50% of US patients in the VALOR study of VLA15 will be discontinued from the trial.

News

Parasitic biting insect on background of epidermis detail. Disgusting carrier of encephalitis, Lyme disease or babesiosis infections. Tick-borne diseases

Pfizer takes stake in French Lyme disease jab partner Valnev...

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme di

News

Readout sets up phase 3 for Valneva/Pfizer's Lyme disease ja...

There's only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer's VLA15 – and it has just moved another step closer to being available.

News

Booster data backs Pfizer, Valneva Lyme disease vaccine

Prospects for Valneva's COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease.

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Data builds behind Valneva, Pfizer's Lyme disease vaccine

Protocol violations gut Pfizer’s Lyme disease shot study

Pfizer takes stake in French Lyme disease jab partner Valnev...

Readout sets up phase 3 for Valneva/Pfizer's Lyme disease ja...

Booster data backs Pfizer, Valneva Lyme disease vaccine

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Lyme disease

Editor's Picks